“…In fact, these intravitreal treatments have been able to dramatically improve patients' visual prognosis, either by increasing their central vision or by preventing further visual loss. Repeated intravitreal administrations of long-acting corticosteroid drugs for treating geriatric patients with chronic diabetic macular edema should be recommended considering that i) the most common comorbidities for DM include microangiopathic disorders (retinopathy, neuropathy, and nephropathy) and macroangiopathic disorders (myocardial infarction, cerebrovascular stroke, and other severe thromboembolic events); ii) the latest guidelines suggest the use of corticosteroids and, in particular, dexamethasone implants, as first-line treatment in diabetic macular edema patients with high cardiovascular risk, and iii) there is insufficient evidence to definitively exclude an increased mortality risk or cardiovascular and cerebrovascular incidents among patients treated with anti-VEGF drugs because affected by diabetic macular edema [23][24][25][26][27][28][29][30][31] . DM is associated with an increased risk of falls due to frailty.…”